Show simple item record

Farmaceutska zdravstvena zaštita u terapiji oralnim kontraceptivima

dc.creatorVezmar, Sandra
dc.creatorMiljković, Branislava
dc.date.accessioned2019-09-02T11:22:19Z
dc.date.available2019-09-02T11:22:19Z
dc.date.issued2010
dc.identifier.issn0004-1963
dc.identifier.urihttp://farfar.pharmacy.bg.ac.rs/handle/123456789/1424
dc.description.abstractThe key role of pharmacists in treatment with oral contraceptives is to educate the patient about possible adverse drug reactions, interactions and their prevention, and to improve compliance. Usual adverse reactions of oral contraceptives include: nausea, break-through bleedings, tense breasts, changes of mood and depression, decreased libido, skin changes, although serious adverse reactions such as myocardial infarction and stroke, venous tromboembolism and hypertension may occur as well. Oral contraceptives are metabolised by several isoenzymes of the cytochrome P-450 which they can also induce or inhibit. Most important interactions occur following coadministration of oral contraceptives and CYP3A4 inducers or CYP2B6 and CYP2C19 substrates. Compliance plays the key role in effective treatment with oral contraceptives but it is commonly unsatisfactory, especially in the adolescent population. Counseling about the importance of adequate administration of oral contraceptives, adverse drug reactions and interactions enables the pharmacist to contribute substantially to effective and safe use of oral contraceptives.en
dc.description.abstractKljučna uloga farmaceuta u terapiji oralnim kontraceptivima je ukazivanje na moguća neželjena dejstva, klinički značajne interakcije i njihovu prevenciju i poboljšanje komplijanse. Uobičajeni neželjeni efekti oralnih kontraceptiva su: mučnina, probojna krvarenja, napetost dojki, promene raspoloženja i depresija, smanjen libido, promene na koži, mada se mogu javiti i veoma ozbiljna neželjena dejstva poput srčanog i moždanog udara, venskog tromboembolizma i hipertenzije. Oralni kontraceptivi se metabolizuju posredstvom niza izoenzima citohroma P 450 koje, takođe, mogu indukovati ili inhibirati. Najznačajnije interakcije nastaju prilikom istovremene primene oralnih kontraceptiva i induktora CYP3A4 ili supstrata CYP2B6 i CYP2C19. Komplijansa u primeni oralnih kontraceptiva je od ključnog značaja za efikasnost lekova ali je često nezadovoljavajuća posebno u populaciji adolescenata. Savetovanjem o značaju pravilne primene oralnih kontraceptiva, neželjenim reakcijama i interakcijama, farmaceut u velikoj meri može doprineti efikasnoj i bezbednoj primeni oralnih kontraceptiva.sr
dc.publisherSavez farmaceutskih udruženja Srbije, Beograd
dc.rightsopenAccess
dc.sourceArhiv za farmaciju
dc.subjectinteractionsen
dc.subjectadverse drug reactionsen
dc.subjectcomplianceen
dc.subjectpharmaceutical careen
dc.subjectoral contraceptivesen
dc.subjectinterakcijesr
dc.subjectneželjena dejstvasr
dc.subjectkomplijansasr
dc.subjectfarmacetuska zdravstvena zaštitasr
dc.subjectoralni kontraceptivisr
dc.titlePharmaceutical care in the treatment with oral contraceptivesen
dc.titleFarmaceutska zdravstvena zaštita u terapiji oralnim kontraceptivimasr
dc.typearticle
dc.rights.licenseBY-SA
dcterms.abstractМиљковић, Бранислава; Везмар, Сандра; Фармацеутска здравствена заштита у терапији оралним контрацептивима; Фармацеутска здравствена заштита у терапији оралним контрацептивима;
dc.citation.volume60
dc.citation.issue2
dc.citation.spage168
dc.citation.epage184
dc.citation.other60(2): 168-184
dc.citation.rankM52
dc.identifier.scopus2-s2.0-77954198817
dc.identifier.fulltexthttp://farfar.pharmacy.bg.ac.rs//bitstream/id/324/1422.pdf
dc.identifier.rcubconv_422
dc.type.versionpublishedVersion


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record